NextLevelHealth
A healthier you. A healthier community.

Provider Memorandum

RE: Aurobindo Pharma USA, Inc. Recalls Ranitidine Tablets, Capsules & Syrup

On November 8, 2019, the U.S. Food and Drug Administration (FDA) announced that Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 1 lot of **Ranitidine Tablets 150 mg** to the retail level and **37 lots of Ranitidine Capsules 150 mg, Ranitidine Capsules 300 mg and Ranitidine Syrup 15 mg/mL** to the consumer level due to the detection of Nitrosodimethylamine (NDMA) impurity in the finished product.

Members who have been prescribed or are taking Ranitidine Tablets 150 mg, Ranitidine Capsules 150 mg, Ranitidine Capsules 300 mg and Ranitidine Syrup 15 mg/mL should continue taking their medication.

Members should contact their pharmacist or provider who can advise them about an alternative treatment prior to returning their medication.

Consumers with medical questions regarding this recall or to report an adverse event can contact Aurobindo Pharma USA, Inc. at: 1.866.850.2876, Option 2.

Providers can review FDA's full press release by visiting:

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-38-lots-ranitidine

For questions or concerns, please reach out to NextLevel Health's Pharmacy Benefit Manager (PBM), Envolve Pharmacy Solutions' Pharmacy Department by calling 1.800.782.2221.

NextLevel Health is committed to improving the health of our Members and providing access to necessary medications.

Sincerely,

Provider Services Department
Nextlevel Health